A pivotal trial of Ruxolitinib for Essential thrombocythemia

Trial Profile

A pivotal trial of Ruxolitinib for Essential thrombocythemia

Planning
Phase of Trial: Phase III

Latest Information Update: 11 May 2017

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Essential thrombocythaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 11 May 2017 New trial record
    • 04 May 2017 According to an Incyte Corporation media release, this program is expected begin in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top